The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a change to the terms of the marketing authorization for Nevanac, according to a summary of opinion from the European Medicines Agency. The recommended change is an extended indication that states “Nevanac 3 mg/mL is indicated in adults for prevention and treatment of postoperative pain and inflammation associated with cataract surgery [and] reduction in the risk of preoperative macular edema associated with cataract surgery in diabetic patients,” the opinion said.
ManagementPlus Launches Revenue Cycle Solutions (RCS) at Optometry’s Meeting
BOSTON–(BUSINESS WIRE)–ManagementPlus, an ECL Group affiliate company and a leader in EHR solutions, announced today that it will launch its Revenue Cycle Solutions (RCS) at the annual Optometry’s Meeting in Boston from June 29-July 3. The company will also be exhibiting at booth #513 and will join hundreds of optometry professionals at the official annual meeting of the American Optometric Association (AOA) and the American Optometric Student Association (AOSA). ManagementPlus incorporates a
The multiple sclerosis drug interferon-β as treatment for age-related macular degeneration?
Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly.
Morning Break: Doc Suicide Film; Stop That or You’ll Go Blind; Insulin Pump Anger
(MedPage Today) — Health news and commentary from around the Web, gathered by the MedPage Today staff
Myopia prevention — from evidence to practice
The worldwide prevalence of myopia is expected to increase from 1.4 billion people at present to 4.7 billion people by 2050. More alarming is the suggestion from a recent meta-analysis that the prevalence of high myopia will increase by more than 300% …
VIDEO: Speaker presents 1 year results from phase 1/2 trial of bimatoprost implant
PRAGUE — At the European Glaucoma Society Congress, Keith Martin, MA, DM, MRCP, FRCOphth, discusses interim 1 year results of the phase 1/2 trial of Allergan’s sustained-release bimatoprost implant for the treatment of glaucoma.